Toward an effective gene therapy in renal disease  by Basile, David P.
Kidney International, Vol. 55 (1999), pp. 740–741
EDITORIAL
Toward an effective gene therapy in renal disease
Since the first reports of the generation of transgenic of extracellular matrix synthesis. Evidence that TGF-b
mice in 1980 [1], technology aimed at manipulating the might contribute to fibrotic renal disease include: (1) the
mammalian genome has yielded fruitful information re- demonstration of enhanced expression of TGF-b peptide
garding the potential physiological roles of gene products and/or mRNA in human renal fibrotic diseases and ani-
in vivo. From these technologies spawned the field of mal models of renal diseases [3]; (2) the demonstration
gene therapy, the goal of which is to treat human diseases that increased TGF-b activity in vivo, by gene transfer
through the introduction of foreign genetic material. The or transgenic methods, results in glomerular extracellular
development of such technology may offer the best hope matrix accumulation, proteinuria, tubulointerstitial fi-
in the future treatment of monogenic diseases such as brosis and the onset of chronic renal failure [4–6]; (3)
cystic fibrosis where current treatments do not address the demonstration that proteinuria and extracellular ma-
the underlying cause. Gene therapy need not solely exist trix (ECM) accumulation associated with anti Thy-1.1
for the treatment of such genetic disorders, but may find nephritis was attenuated by a neutralizing antibody to
widespread utility in treating acquired diseases in which TGF-b or the TGF-b antagonist, decorin [7, 8]. Thus,
a protein is under- or over-expressed. strategies that intervene with TGF-b extracellularly may
Despite the ever-increasing knowledge of the genetic be of therapeutic utility.
nature of diseases (that is, the identification of “culprit” In this issue of Kidney International, Isaka et al report
genes which lack proper function or proper expression), a novel and exciting twist on gene therapy strategies
several practical considerations have kept gene therapy designed to reduce TGF-b hyperactivity in a rat model
a “future prospect.” These considerations include: (1) of glomerulonephritis [9]. TGF-b’s biological effects are
the method of introduction of foreign genetic material; manifested through signal-transducing receptors on the
(2) the ability to target the expression of genetic material cell surface which are referred to as TGF-b receptors
to relevant cell types; (3) the demonstration of practical- type I and II, (TbRI and TbRII). While both receptor
ity in animal models of diseases; (4) the ability to utilize subtypes possess serine kinase domains, active TGF-b
this technology in patients without severe side-effects. has strong affinity for the extracellular domain of TbRII
The reader is referred to the excellent article by Lipko- and only interacts with TbRI after association with
witz et al [2] that outlines several advances in these first TbRII on the cell surface. It has been shown that a
two considerations. Several options such as the adenovi- soluble recombinant peptide containing the ligand bind-
rus, adeno-associated virus, retroviruses or the direct ing domain of TbRII competitively inhibits TGF-b activ-
injection of DNA using lipofection reagents, continue ity in vitro [10].
to be refined as a means to introduce foreign DNA into The report by Isaka et al [9] takes advantage of this
mammalian cells. Furthermore, tissue and cell specificity, observation. The authors have designed a chimeric gene
at least in kidney, appear likely to be achieved via a product containing the ligand binding domain of the
combination of cell-specific promoters in combination TbRII molecule with the Fc region of the IgG heavy
with the proper vector and physical route of administra- chain that contains intermolecular cysteine disulfide
tion [2]. Experiments geared toward demonstrating the bonds. The resulting stabilized chimeric dimer is a potent
practicality of a genetic approach toward therapy in ani- competitive inhibitor of TGF-b in vitro. Following trans-
mal models of renal disease would appear to be the next fection into muscle in vivo, the expressed protein is re-
major step. leased extracellularly and is detected in kidney glomer-
The problem of target specificity appears less impor- uli. Its efficacy was determined by administration of the
tant when humoral factors are involved. Evidence has chimeric construct one day after treatment with anti-
accumulated suggesting a key role for transforming Thy 1.1 serum to rats. These animals manifested signifi-
growth factor-beta (TGF-b) as a possible mediator of cantly less glomerular matrix expansion than mock-vec-
several renal fibrotic diseases of both glomerular and tor treated controls. This same group of investigators
tubular origin. In vitro, TGF-b is a potent stimulator has published similar findings following the in vivo trans-
fection of the natural occurring TGF-b inhibitor, decorin
[11]. Therefore, this report strengthens the argumentKey words: genetics, transforming growth factor-b, fibrotic renal dis-
ease, transgenic method, chimeric gene product. that TGF-b be considered a molecular target in the set-
ting of renal fibrotic disease. 1999 by the International Society of Nephrology
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